Drugs / horse anti-thymocyte globulin (hATG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02462252 Background | Oct 2015 → Nov 2020 | aplastic anemia, myelodysplastic syndrome | BioLineRx, Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | horse anti-thymocyte globulin (hATG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02462252 ↗ |
| Known as | hATG | “horse anti-thymocyte globulin (hATG)” NCT02462252 ↗ |